Does Pediatrix Medical Group (MD) Stock Look Better After Q1 Report?

Pediatrix Medical Group Inc (NYSE:MD) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. Pediatrix Medical Group Inc (NYSE:MD) has soared roughly 56% over the past year, and analysts see more upside potential in it.

Pediatrix Medical Group released its Q1 2026 financial results on May 5. It delivered revenue of $476.2 million, an increase from $458.4 million in the same period the prior year. The revenue also came well above the $465.7 million that analysts expected.

The management attributed the increase to growth in same-unit revenue as well as recent acquisitions. The company posted adjusted EBITDA of $58.2 million, compared with $49.2 million a year ago. Again, the management said favorable same-unit results and recent acquisitions drove the increase in adjusted EBITDA.

Net income was $29.6 million, or $0.36 per share, reflecting an increase from $20.7 million, or $0.24 per share in the same quarter a year ago. Adjusted EPS of $0.44 rose from $0.33 a year ago and surpassed the Street’s expectation of $0.38. The company wrapped the quarter with a cash balance of $205.8 million and $224.8 million in net accounts receivable.

Looking ahead, Pediatrix Medical Group is anticipating full-year 2026 adjusted EBITDA between $280 million and $300 million. The company’s CEO Mark S. Ordan said that robust cash flow and a solid balance sheet positions them well to “find new opportunities and move decisively.”

Pediatrix Medical Group Inc (NYSE:MD) is a medical practice company. It partners with hospitals and healthcare facilities to provide specialist medical care to women, babies, and children. This physician-led practice group operates in 37 states and has hundreds of hospital partners.

READ NEXT: 7 Best Small Cap Agriculture Stocks to Buy Now and 8 Best Gold Stocks Under $5.

Disclosure: None. Follow Insider Monkey on Google News.